Recent Patents on Regenerative Medicine - Volume 4, Issue 2, 2014

Cancer stem cells (CSCs), a highly clonogenic subpopulation of tumour cells are held to be one of the biggest causes of cancer relapse, metastasis and subsequent mortality. The increasing emergence of evidence in support of the CSC hypothesis has had dramatic implications on our understanding of disease progression and it also offers us the opportunity to develop novel therapeutics that specifically target and erad Read More

Regeneration of bone lost through pathological and/or traumatic events is a complex process due to the intricate, dynamic nature of the skeleton. Although osseous tissue has the ability in many circumstances to organize its own regeneration, tissue engineering, particularly of large, critical size defects, can be optimized by clinical intervention. Products have been developed to aid in the repair and regeneration of bone based on Read More

Barrier membrane technology, gene delivery and stimulatory proteins for cell growth and metabolism are potential methods for enhancing periodontal regeneration. Factors that contribute to growth and differentiation of connective tissue and bone regulate diverse cells of periodontal origin. Although these agents have significant appeal in promoting periodontal wound healing and bone regeneration, the outcome of cu Read More

Stimulation of damaged muscle tissue regeneration and repair of functional skeletal muscle by methods of regenerative medicine (cell and tissue therapy, tissue engineering) are topical problems of today. Efforts of scientists and physicians are focused on the developments for identifying, isolating, expanding competent myocytes and stem cells from biopsy material, for creating secure stem cell culture conditions and for f Read More

Each year in the United States alone, for about 50 million surgeries is undertaken. An extra 50 million traumatic wounds increased further the burden of morbidity stemming from acute wounds. For instance, chronic ulcers are a growing cause of significant patient morbidity and mortality. Pentoxifylline, a xanthine derivative, is a non-selective phosphodiesterase inhibitor that raises intracellular cyclic adenosine monophosph Read More